Hydralazine
Hydrazinophthalazine Derivatives
- Drug class
- Hydrazinophthalazine Derivatives
- Availability
- Prescription only
- Routes
- Oral, Intramuscular, Intravenous
- Markets covered
- 3
- Products on record
- 21
Overview
Plain-language summary, compiled from the cited regulatory records
Hydralazine is a medication classified as a hydrazinophthalazine derivative [1]. It is approved for the treatment of essential hypertension, meaning high blood pressure, and can be used either as a standalone therapy or in combination with other medications [1].
This active ingredient is available under various brand names [1]. While specific examples were not provided in the data, it is recognized that multiple formulations exist in the market.
In the past 12 months, there were no adverse event reports submitted for hydralazine [2]. This data point reflects the number of reports received and does not represent the total incidence of adverse events.
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| US United States | FDA | 10 | December 26, 2025 |
| GB United Kingdom | MHRA | 7 | May 1, 2026 |
| CA Canada | Health Canada | 4 | March 22, 2025 |
USUnited States· FDA
10 products
Uses
INDICATIONS AND USAGE
Essential hypertension, alone or as an adjunct.
How to take
GBUnited Kingdom· MHRA
7 products
Uses
Hydralazine is indicated for: 1) Moderate to severe hypertension as an adjunct to other anti-hypertensive agents. Due to the complementary mechanism of action the combination of hydralazine with b- blockers and diuretics may enable antihypertensive efficacy at lower dose levels and counteract accompanying hydralazine effects such as reflex tachycardia and oedema.
2) As supplementary medication for use in combination with long-acting nitrates in moderate to severe chronic congestive cardiac failure in patients in whom optimal doses of conventional therapy have proved insufficient.
How to take
CACanada· Health Canada
4 products
Uses
, toxemia of pregnancy or pre-eclampsia). 1 Pediatrics No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 2 Geriatrics Geriatric patients or patients with marked renal damage may require a lower dosage.
How to take
Drug interactions
Known interactions involving Hydralazine. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 282. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]FDA DailyMed · 024ac6b8-5ce0-44… · revised July 1, 2025 [PDF]
- [2]MHRA (UK) · PL001420499 · revised May 1, 2026
- [3]Health Canada (DPD) · 02406012 · revised March 22, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.